<DOC>
	<DOCNO>NCT01535235</DOCNO>
	<brief_summary>The investigator propose proof-of-concept , pathogenesis-oriented , randomize , placebo-controlled pilot study ass whether addition angiotensin convert enzyme ( ACE ) inhibitor standard Highly Active Antiretroviral Therapy ( HAART ) reverse lymphoid fibrosis , whether lead effective HIV-specific host immune response accelerate clearance latent reservoir .</brief_summary>
	<brief_title>ACE Inhibitors Decrease Lymphoid Fibrosis Antiretroviral-Treated , HIV-infected Patients : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<criteria>Inclusion Criteria include : Stable HAART maintenance plasma HIV RNA level level detection ( &lt; 4075 copies/mL ) â‰¥ 12 month &gt; 90 % adherence HAART within precede 30 day Exclusion Criteria include : Screening systolic blood pressure &lt; 110mm Hg diastolic blood pressure &lt; 60mm Hg Current use ACE inhibitor , angiotensin receptor blocker , aldosterone antagonist Known diabetes mellitus cardiovascular/kidney/collagen vascular disease Pregnant/breastfeeding woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Lymphoid fibrosis</keyword>
</DOC>